1. Home
  2. BHVN vs IOVA Comparison

BHVN vs IOVA Comparison

Compare BHVN & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biohaven Ltd.

BHVN

Biohaven Ltd.

N/A

Current Price

$10.76

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

N/A

Current Price

$2.37

Market Cap

881.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BHVN
IOVA
Founded
2013
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
881.3M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
BHVN
IOVA
Price
$10.76
$2.37
Analyst Decision
Buy
Buy
Analyst Count
15
12
Target Price
$30.36
$10.45
AVG Volume (30 Days)
2.9M
12.7M
Earning Date
03-02-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$250,425,000.00
Revenue This Year
N/A
$60.71
Revenue Next Year
N/A
$59.35
P/E Ratio
N/A
N/A
Revenue Growth
N/A
175.62
52 Week Low
$7.48
$1.64
52 Week High
$44.28
$6.16

Technical Indicators

Market Signals
Indicator
BHVN
IOVA
Relative Strength Index (RSI) 45.86 47.81
Support Level $10.61 $2.25
Resistance Level $12.90 $2.77
Average True Range (ATR) 0.80 0.22
MACD -0.23 -0.03
Stochastic Oscillator 17.66 31.01

Price Performance

Historical Comparison
BHVN
IOVA

About BHVN Biohaven Ltd.

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Share on Social Networks: